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ABSTRACT 
Objective: The present study aimed to determine whether type 2 diabetes mellitus influences the response to antiviral therapy with peg-interferon 
alpha plus ribavirin in Egyptian patients with chronic hepatitis C.  
Methods: All patients were treated with peginterferon alpha 2 b (1.5 μg/Kg/body weight) subcutaneously plus oral ribavirin application in a dose 
ranging from 800-1200 mg/day and followed after 12 w of therapy. 
Results: The present study indicated that, non-significant changes were observed in liver function, kidney function, thyroid function tests, tumor 
marker, immunological analysis, hematological parameters, viral load and degree of cirrhosis between both groups’ baselines, while the only 
significant difference was regarded in glucose level. However, diabetic group showed a significant decrease in response to antiviral therapy as 
compared to non-diabetic hepatitis C virus (HCV) patients. Furthermore, significant decrease in serum liver enzymes activity and total bilirubin 
level as compared to baseline levels in both groups, while there were a significant increase in alanine transaminase (ALT) activity and total bilirubin 
level in diabetic group as compared to non-diabetic HCV group after treatment. Also, significant decreases in hemoglobin concentration, white blood 
cells and platelet counts, in both groups after treatment as compared to there before treatment while diabetic group showed significant decreases in 
hemoglobin concentration and white blood cells count when compared with non-diabetic HCV group after treatment.  
Conclusion: Type 2 diabetes mellitus influence the response to antiviral therapy with peginterferon plus ribavirin in Egyptian patients with chronic 
hepatitis C. 
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INTRODUCTION 
Chronic hepatitis C virus (CHCV) infection is gaining increasing 
attention as global health problem affects approximately 170 million 
people worldwide and long-term carriage may lead to the 
development of cirrhosis, liver decompensation and hepatocellular 
carcinoma, a major indication for liver transplantation [1]. 
Epidemiological studies indicate that each year approximately 3-4 
million people worldwide are affected and>350000 individuals die 
due to liver disease [2]. There are 11 genotypes; genotypes 1‑3 have 
a worldwide distribution accounting for 60-70 % of infections; type 
3 predominantly seen in south ‑ east Asia, type 4 restricted to Middle 
East and Africa. Genotypes 2 and 3 accounts for<30 %; whereas<1 % 
of total infection by genotype 5‑ 11 [3]. Egypt reports the highest 
prevalence of HCV worldwide, an average of 13.8 % with the 
predominant prevalence being infection with genotype 4a [4].  
The link between chronic hepatitis caused by hepatitis C virus 
infection and type 2 diabetes mellitus has been suggested. Several 
studies have reported a higher prevalence of hepatitis induced by 
HCV in diabetic patients compared with control groups and other 
studies had found that there was a higher prevalence of diabetes 
mellitus in patients with chronic hepatitis C virus infection [5]. 
Additionally, type 2 diabetes (NIDDM) and insulin resistance (IR) are 
independent predictors of a more rapid progression of liver fibrosis 
and impaired response to antiviral treatment in chronic hepatitis C. 
In addition, IR and NIDDM not only accelerate the histological and 
clinical progression of chronic hepatitis C, but also reduce the early 
and sustained virological response (SVR) to interferon-alpha-based 
therapy [6]. As many as 80 % of patients with cirrhosis show glucose 
intolerance, and 10–20 % of them have diabetes mellitus [7]. Rapid 
virological response-undetectable HCV-RNA by polymerase chain 
reaction tests after the initial 4 w of treatment is an excellent 
positive predictor of SVR [8]. 
Interferon (IFN) induced thrombocytopenia and leucopenia is 
common, whereas anemia is more a sequel of combination therapy 
with ribavirin [9]. Moreover the main mechanism leading to 
hematological abnormalities during IFN therapy seems to be bone 
marrow suppression by IFN [10]. Although treatment-related side 
effects can make therapy unpleasant, most do not necessarily lead to 
discontinuation of therapy [11]. The goal of the present work is to 
determine the influence of type 2 diabetes mellitus on antiviral 
therapy with peginterferon alpha plus ribavirin in chronic hepatitis 
C patients. 
MATERIALS AND METHODS 
The participants in the study included 40 patients selected as out-
patients at the hepatology division of Beni-Sueif general hospital. 
Permission from the authority of the hospital is to work protocol, is 
done and also every patient is accepting the investigations according 
to the medical ethics.  
The patients were classified into two groups as the following:  
Group I: included 20 patients with chronic hepatitis C with diabetes 
mellitus. 
Group II: included 20 patients with chronic hepatitis C without 
diabetes mellitus. 
Inclusion criteria 
• Patients with chronic hepatitis C antibody positive and hepatitis B 
surface antigen negative. 
• Patients with detectable HCV-RNA-PCR. 
• Patients matching as regarding to age, viral load and the degree of 
inflammation and fibrosis. 
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• Patients with an established diagnosis of diabetes mellitus. 
Patients were diagnosed as having diabetes mellitus according to 
one of the classification criteria of the American Diabetes 
Association. 
A-Random plasma glucose concentration ≥ 200 mg/dl (≥ 11.1 
mmol/l), or 
B-Fasting plasma glucose level ≥ 126 mg/dl (≥7.0 mmol/l). Or 
C-Two hour’s post-load plasma glucose level ≥ 200 mg/dl (≥ 11.1 
mmol/l) during an oral glucose tolerance test [12].  
Exclusion criteria 
• Patients with other causes of chronic liver disease are excluded 
including hepatitis B virus infection (positive for hepatitis B surface 
antigen), drug-induced liver disease. 
• Patient with advanced cirrhosis. 
• Patient with hepatocellular carcinoma (HCC). 
• Patients with serious complications in the heart, kidneys, or lungs. 
• Patients with thyroid dysfunction. 
• Patients with autoimmune diseases, such as autoimmune 
hepatitis. 
• Patients with blood picture abnormalities such as anemia 
(hemoglobin concentration of 10 g/dl or less), leucopenia (white 
blood cells 1500/dl or less) and thrombocytopenia (platelets count 
80.000/dl or less). 
Treatment protocol 
All patients were received peginterferon (Peg-IFN) and ribavirin 
(RBV) combination therapy. Peg-interferon-alpha 2b was given in 
weekly doses (1.5 μg/Kg/body weight). RBV was given in daily 
doses adjusted to body weight according to manufacturer’s 
instructions (11 mg/kg/day). After 12 w of treatment, the virological 
response was recorded according to [13]. 
Sample collection 
Venous blood sample collected from each subject before treatment 
was separated in a three tubes containing anti-coagulant (sodium 
florid) for measuring the fasting blood glucose or anti-coagulant 
(EDTA) for measuring the hematological parameters. The blood in the 
last tube allowed to clotting then centrifuged to separate the serum, 
for the other tests. And all tests were done in Beni-Suief general 
hospital. The samples were collected prior the starting of treatment to 
determine the recommended baseline laboratory tests included in the 
treatment approval form of National Hepatology for Tropical Medicine 
and Research Institute (TMRI) for patients with chronic HCV infection 
who are being considered for antiviral therapy. Chronic hepatitis C 
patients who had contraindications to interferon can’t be treated with 
the antiviral combination therapy. After 12 w of treatment another 
blood samples was collected from patients to evaluate the virological, 
biochemical and hematological responses. 
Parameters investigated before and after treatment 
Viral load 
Hepatitis C virus RNA (HCV-RNA), (REAL TIME PCR) 
Hepatitis C virus RNA was carried out by using nested PCR, which 
was performed parallel with positive and negative controls on light 
cycler Real-Time and on–line quantification using Roche Amplicor 
HCV monitor version 2.0 (Roche Diagnostics, Branchburg, NJ) for 
measurements. The low limit of detection was 50 IU/ml.  
Biochemical parameters 
Estimation of serum aminotransferases (ALT), (AST) 
Determination was done according to [14] using Kits of noble 
diagnostic, Egypt. Chemical analyzer (HERA, Linear chemicals, S. L. 
Spain) was used for measuring biochemical parameters. 
Determination of serum bilirubin 
The test performed according to [15] using kits of diamond 
diagnostic, Egypt.  
Hematological parameters 
The hematological parameters include measurement of hemoglobin 
concentration, white blood cell count and platelets count according 
to [16] using a cell counter instrument (HeCo SEAC).  
Parameters investigated before starting the treatment 
The following parameters were investigated according to the 
approval form of National Hepatology for Tropical Medicine and 
Research Institute (TMRI), as a pre-enrollment data for patients who 
are being considered for antiviral therapy.  
Hepatitis C virus antibodies (anti–HCV) 
Hepatitis C virus antibodies were performed with a third–generation 
ELISA according to [17] using the instrument READER, 2000 and 
HCV BIO kits S. A Barcelona. 
Hepatitis B surface antigen (HBs Ag) 
Hepatitis B surface antigen was performed by enzyme linked 
immunosorbant assay according to [18] using the instrument 
Radium, Germany. 
Serum albumin 
The test was performed according to [19] using kits of Diamond 
Diagnostic, Egypt. 
Serum alkaline phosphatase (ALP) 
Estimation was done according to [14] using kits of Bio System, 
Spain.  
International normalized ratio (INR) 
The test was performed according to [20] using kits of Dia-Med, 
Switzerland.  
Fasting plasma glucose 
Estimation was done according to [15], using kits purchased from 
Diamond Diagnostic, Egypt.  
Serum creatinine 
The test was investigated according to [21] using kits purchased 
from Diamond Diagnostic, Egypt. 
Serum alphafetoprotien (AFP) 
Determination was done according to (22) using kits of VIDAS bio-
Merieux, France and Mini VIDAS instrument. 
Thyroid stimulating hormone (TSH) 
The test was done using kits of VIDAS bio-Merieux, France. The 
assay principle combines a one–step enzyme immunoassay 
sandwich method with a final fluorescent detection ELFA (Enzyme 
Linked Fluorescent Assay) according to [23]. The test was done 
using Mini VIDAS instrument.  
Anti-nuclear antibody titer (ANA) 
The parameter was investigated according to [24] using kits of Bio-
Quant-U S and the automated ELECSYS 1010, Roche instrument.  
Anti bilharzial antibodies 
Determination was done according to [25] using Kits of FUMOUZE 
diagnostic, France. The principle based on indirect 
hemoagglutination. 
Ultrasonographic guided needle liver biopsy 
Percutaneous needle biopsy was performed under ultrasound 
guidance because of lower rate of complication [26]. A satisfactory 
biopsy is 1-4 cm long. In general a biopsy of 1.5 cm with four to six 
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portal tracts is sufficient for histological assessment of chronic 
hepatitis. The liver biopsies were scored using the Ishak modified 
HAI [27]. 
Ethical aspects 
• All patients have given a written consent as regard the 
participation in the study and having the right to withdraw from the 
study, according to an ethics committee of hepatology unit, in Beni-
Sueif general hospital. 
• All the selected patients have given a written consent as regard 
to liver biopsy. 
• For the matter of confidentiality, the clinical assessment and 
transformation of data were done by the researcher.  
Statistical analysis of the results 
Data was collected coded and analyzed using SPSS software version 
17 under Windows Vista. Descriptive analysis of the results was 
done in the form of percentage distribution for qualitative data, and 
mean and standard deviation calculation for quantitative data. It was 
followed by applying the suitable tests of significance for the 
comparison between different groups and 95 % level of significance 
is considered (SPSS version 17 SPSS INC., Chicago, IL, USA). The 
following tests of significance were used: Fisher’s Exact Test, 
Student t-test and Paired t-test. The results were expressed as the 
mean±standard deviation (SD) and values of P>0.05 were 
considered statistically non-significant (N. S.), while values of P 
value<0.05, 0.01, 0.001 were considered statistically significant 
(Sig). 
RESULTS 
Baseline pretreatment assessment included complete blood picture, 
liver and kidney functions, quantitative HCV-PCR, TSH levels, the 
liver biopsy while, Liver functions, CBCs and quantitative HCV–PCR 
and followed up after 12 w of treatment.  
Baseline parameters before treatment  
• Demographic distribution 
In the study, the patient's demographic distribution was as follows:  
There were no significant differences in the age or sex between the 
two groups p value (>0.05) as shown in table (1). 
• Laboratory investigation 
Patients included in the study, screened for hepatitis C virus 
antibodies were positive for HCV abs. and all patients were negative 
for hepatitis B surface antigen.  
As shown in table (1), the base line data collected from both groups 
before treatment indicated that there was a significant difference (p 
value<0.05) regarding fasting blood glucose and a non-significant 
statistical difference (p value>0.05) was found regarding sex, age, 
serum creatinine, serum albumin, serum alkaline phosphatase, 
serum AST, serum ALT, total bilirubin, indirect bilirubin, total 
leucocytes count, hemoglobin concentration, platelets count, INR, 
ANA titer, TSH, alpha-fetoprotein, viral load and the degree of 
cirrhosis. The two groups before treatment have the same baseline 
of biochemical and hematological features, and also the same degree 
of cirrhosis and viral load and all patients had no contraindication 
for antiviral combination therapy. 
Study of the variable responses of both groups after treatment  
Effect of antiviral treatment on biochemical parameters 
• Effect on serum glutamate pyruvate transaminase activity 
(ALT) 
In our study, a normalization of serum alanine transaminase was 
observed after 12 w of antiviral combination therapy. The decrease 
in ALT activity of group one after treatment as compared to ALT 
activity before treatment was highly significant as shown in table 
(2). Also, group two showed a highly significant decrease in ALT 
activity after treatment as compared to their activity before 
treatment as represented in table (3). 
• Effect on serum glutamate oxaloacetate transaminase activity 
(AST) 
A normalization of AST was observed after 12 w of antiviral 
combination therapy. The decrease in AST activity was highly 
significant in group I after treatment as compared to AST activity 
before treatment, as represented in table (2). Group II also showed 
a highly significant decrease in AST activity after treatment as 
compared to AST activity before treatment, which observed in 
table (3). 
• Effect on total bilirubin 
In group I bilirubin concentration showed a significant decrease 
(<0.001) after treatment as compared with before treatment (table 
2). Furthermore, group II showed a significant decrease in total 
bilirubin after treatment as compared to before treatment (table 3). 
Effect of antiviral treatment on viral load 
Table 4 shows the evaluated measurements of serum HCV RNA as a 
predictor of response 12 w after starting antiviral therapy. Group II 
revealed a clearance to be of 95 % while in group I the clearance 
with 65 % significantly lower (P<0.05). Furthermore, patients with 
lower pre-treatment HCV-RNA concentration had a high likelihood 
of achieving a sustained response. 
Effect of antiviral treatment on hematological parameters 
• Effect on hemoglobin  
In the present study, a significant decrease (<0.001) in hemoglobin 
concentration after treatment in group I was detected as compared 
to that before treatment (table4). Anemia with hemoglobin (Hb) 
levels below 10 gm was detected in 5 cases (32 %) after weeks 12 of 
treatment. In group II, also indicated a significant decrease in 
hemoglobin concentration after treatment compared with that 
before treatment (table 5). 4 cases (16 %) showed hemoglobin less 
than 10 mg/dl, while 1 case showed marked anemia and forcing the 
discontinuation of treatment. 
• Effect on platelets  
Patients with chronic hepatitis C showed after treatment with 
peginterferon and ribavirin a significant decrease (<0.001) in 
peripheral platelets compared to that before treatment in group I as 
shown in table (4). However, in 15 % of cases platelet count was less 
than 120.000 cells/ml3. Group II, showed also a significant decrease 
in peripheral platelets after treatment compared to that before 
treatment (table 5). On an other hand, in 25 % of all cases there was 
platelet count less than 120.000 cell/ml3. 
• Effect on leucocytes 
Treatment with peginterferon and ribavirin decreased in group one 
white blood cells counts significantly (<0.001) as represented in 
table (4). 28 % of cases showed leucocytes count less than 3000 
cell/ml3. Group II revealed also, a significant decrease in white blood 
cells count after treatment as compared to before treatment as 
illustrated in table (5).  
Comparison between the two groups after treatment 
As shown in table (6), there were significant differences (p 
value<0.05) between group I and II concerning various parameters. 
The mean values of ALT, total bilirubin and WBCs were significantly 
higher in group I than in group II. There were no significant 
differences between groups in AST, hemoglobin and platelets count. 
DISCUSSION 
HCV genotype 4 is prevalent in Egypt which is responsible for more 
than 90 % of infection and is considered as a major cause of chronic 
hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) and 
liver transplantation [28]. The current treatment for patients with 
chronic hepatitis C genotype 4 is a combination therapy using 
subcutaneous peg-interferon (PEG-IFN), together with oral ribavirin 
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(RBV) for 24 to 48 w. Moreover, 12 w of antiviral therapy HCV-RNA 
should be tested to determine the viral response. If the HCV-RNA 
level at 12 w has decreased to less than 2 log10 IU/ml compared 
with the pretreatment HCV-RNA level, it is advised to stop treatment 
because an SVR will rarely occur [29]. The effectiveness of antiviral 
treatment, the extent to which treatment can clear the viral infection 
is assessed according to the proportion of patients achieving 
sustained virologic response (SVR). SVR is the fundamental goal of 
treatment and is defined as undetectable (or below the lower limit of 
quantification) HCV RNA at 12–24 w after cessation of 
treatment [30]. A link between chronic hepatitis caused by chronic 
hepatitis C infection and type2 DM has recently been suggested. 
Several studies have reported a higher prevalence of hepatitis 
induced by HCV in diabetic patients compared with control groups. 
Others had found the higher prevalence of DM in patients with 
chronic HCV infection [5, 31]. 
  
Table 1: The base lines of several parameters of group 1 as compared to group 11 before treatment 
Base line data 
 
Group I Group II 
mean±SD mean±SD 
Age 46.25±4.2 45.20±5.2 
Glucose (mg/dl) 152.5±19.8** 83.65±10.7 
Creatinine(mg/dl) 0.88±0.16 0.84±0.14 
Albumin(g/dl) 3.89±0.18 3.94±0.30 
Alkaline ph(U/l) 140.60±27.5 138.30±24.0 
AST (U/l) 79.00±10.9 72.60±12.2 
ALT (U/l) 99.00±15.1 92.05±10.9 
Total bilirubin(mg/dl) 1.3±0.21 1.23±0.20 
direct bilirubin(mg/dl) 0.46±0.13 0.43±0.11 
INR 1.26±0.08 1.23±0.14 
Alpha-fetoprotein 9.0±1.1 8.5±1.06 
TSH 1.7±0.36 1.9±0.47 
WBCs(cell/ml3) 6074±1161 6047±1030 
HB (g/dl) 14.12±0.87 13.34±1.47 
PLT (cell/ml3) 209300±19431 215900±24065 
HCVRNA x103(IU/ml) 655.457±121.158 508.638±101.732 
Degree of cirrhosis 1.85±0.34 1.70±0.30 
Data expressed as mean and±SD. Number of patients in each group were twenty. P*<0.05, p**<0.01, P<0.001 
Group I: patients with chronic hepatitis C with diabetes mellitus, Group II: patients with chronic hepatitis C without diabetes mellitus.  
 
Table 2: Effects of treatment on some liver function parameters of Group I 
Parameter Group I before treatment (control) Group I after treatment 
mean±SD mean±SD 
ALT(U/l) 99.0±15.13 27.05±6.67** 
AST (U/l) 79.0±10.95 30.20±8.97** 
T bilirubin (mg/dl) 1.3±0.21 0.83±0.16** 
Data expressed as Mean and±SD. Number of patients in each group was twenty. P*<0.05, p**<0.01, P<0.001 
 
Table 3: Effects of treatment on some liver function parameters of Group 1I 
Parameter  Group II before treatment (control) Group II after treatment 
mean±SD mean±SD 
ALT (U/l) 92.05±10.99 23.50±6.35** 
AST (U/l) 72.60±12.22 24.95±3.84** 
T bilirubin (mg/dl) 1.23±0.2 0.70±0. 12** 
Data expressed as Mean and±SD. Number of patients in each group was twenty. P*<0.05, p**<0.01, P<0.001 
 
Table 4: Hematological results of Group I before and after treatment 
Parameter Group I before treatment (control) Group I after treatment 
mean±SD mean±SD 
WBCs(cell/ml3) 6074±1161 3232±590** 
HB(mg/dl) 14.12±0.87 10.19±1.07** 
Platelets(cell/ml3) 209300±19431 156300±28394** 
Data expressed as Mean±SD Number of patients in each group was twenty. P*<0.05, p**<0.01, P<0.001. 
 
Table 5: Hematological results of Group II before and after treatment 
Parameter Group II before treatment (control) Group II after treatment 
mean±SD mean±SD 
WBCs(cell/ml3) 6047±1230 3690±415** 
HB(mg/dl) 13.34±1.47 10.86±1.33** 
Platelets(cell/ml3) 215900±24065 168500±28162** 
Data expressed as Mean and±SD. Number of patients in each group was twenty. P*<0.05, p**<0.01, P<0.001 
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Table 6: Comparison of mean rank of change of group 11 as compared to group 1 parameters after treatment 
Parameter Group I after Group II after 
mean±SD mean±SD 
ALT(U/l) 30.20±8.97 23.50±6.35* 
AST(U/l) 27.05±6.67 24.95±3.84 
Total bilirubin(mg/dl) 0.83±0.16 0.76±0.12* 
WBCs(cell/ml3) 3232±590 3690±415* 
HB (mg/dl) 10.19±1.07 10.86±1.33* 
Platelets (cell/ml3) 156300±28394 168500±28162 
Data expressed as mean and±SD. Number of patients in each group were twenty. P*<0.05, p**<0.01, P<0.001 
 
Data of the present study indicated that there were a non-significant 
difference between both groups in alkaline phosphatase (ALP) 
activity and ALP activity was within normal ranges in most cases. 
Furthermore, non-significant differences between both groups were 
observed in total bilirubin, direct bilirubin, albumin concentrations 
and international normalized ratio (INR). These results are 
consistent with results of [32] who reported that alkaline 
phosphatase; total and direct bilirubin, albumin concentration and 
INR are usually within normal ranges in chronic hepatitis C patients. 
The author data indicated that elevation of ALP; total and direct 
bilirubin and INR may indicate cirrhosis of liver cells [32]. Albumin 
levels, bilirubin, and pro-thrombin time are normal until late-stage 
disease [33].  
Present data indicated that there was a non-significant difference in 
alpha fetoprotein (AFP) between both groups, and both groups 
showed a normal value in comparing to normal ranges. This 
indicated that all patients have no evidence of hepatocellular 
carcinoma (HCC). Also, there was a non-significant difference in 
thyroid stimulating hormone (TSH) and anti-nuclear antibodies 
values in both groups. Also, there was non-significant change in 
creatinine concentration between both groups. And levels of AFP, 
TSH, ANA and creatinine were within normal ranges and not contra 
indicated to antiviral treatment. 
The current investigation showed a significant increase in ALT 
ranging from 1 to 3 times of the upper limit of normal reference 
ranges in group one and group two. There was non-significant 
difference between both groups in ALT activity. Also, there were a 
significant increases in AST range from 1 to 2 times of the upper 
limit of normal ranges in group one and group two, and non-
significant difference between both groups in AST activity. 
Moreover, serum ALT levels are usually higher than AST levels. 
These data agree with [32] who reported that increases in the ALT 
and AST range from zero to 20 times (but usually are less than five 
times) of the upper limit of normal in CHC but that finding may be 
reversed in patients who have cirrhosis [33]. Chronic infection 
causes mild chronic inflammation of the liver and leakage of liver 
enzymes, ongoing cycles of inflammation, necrosis and apoptosis 
eventually leading to scarring (fibrosis) and, ultimately, severe 
bridging fibrosis with nodular regeneration [34]. Above data showed 
non-significant changes between groups in biochemical baseline 
tests in between both groups.  
In the present study, after 12 w of antiviral combination therapy a 
highly significant decrease in ALT and AST activities was observed in 
both groups after treatment as compared to their activity before 
treatment. As transaminases, bilirubin concentration showed also a 
highly significant decrease after treatment as compared with before 
treatment in both groups 
Our findings are in accordance with [35], who reported that a 
virological response to peg-interferon and ribavirin is typically 
associated with a decrease in serum transaminases. Also, [36] found 
that the decline rates of ALT from baseline to week 2 and 4 of INF 
and RBV combination therapy are good predictors of an SVR. Also, 
[37] studied one hundred seven patients with chronic Hepatitis C 
(genotype 1), and recorded that all liver tests return to normal with 
eradication of the Hepatitis C virus. When comparing both groups 
with each other after treatment in response to antiviral treatment, 
the presented data showed that there were significant increases in 
the mean change of ALT activity and total bilirubin in group one in 
comparing with group two. However, there were a non-significant 
difference in the mean change of AST activity during the course of 
treatment in group one as compared to group two after treatment. 
The results of this investigation is in accordance with the results of  
[35] who reported that transaminases elevations were associated 
with greater pre-treatment body weight, insulin resistance, and 
poorer sustained virological response rates. Since HCV promotes 
insulin resistance and insulin resistance induce fibrosis and 
interferon resistance resulting in poor virological response [38].  
Transaminases elevations during treatment of chronic hepatitis C 
virus with peg-interferon and ribavirin are common but rarely 
severe in the present study there were 4 cases of group one showed 
increase in ALT activity. This mild rises may reflect ongoing viral 
activity in treatment non-responders. Highly significant increase is 
frequently observed despite a virological response, and may be 
because of an immuno-modulating effect of interferon in susceptible 
patients [35]. These findings are in accordance with [39], who 
reported that Serum ALT level became normal by the end of 
treatment in 80 of the 110 patients (73 percent).  
Hepatitis C Virus (HCV) infection appears to confer increased risk of 
diabetes mellitus beyond established risk factors and is associated 
with severity of liver disease [40]. Delayed biochemical response 
was associated with the baseline hepatic fibrosis stage and liver 
cirrhosis [41]. The present data demonstrated that the biochemical 
response to antiviral therapy in group two was better than group 
one. This agrees with [6] who reported that T2DM accelerate the 
histological and clinical progression of chronic hepatitis C and 
reduce the response to therapy in CHC patients. From the above 
mentioned results, after 12 w of antiviral therapy a normalization of 
liver tests occurred, and diabetic group showed a delayed 
biochemical response. 
In the presented study, there were non-significant changes in white 
blood cells (WBCs) count; hemoglobin concentration and platelets 
count between both groups before starting the antiviral therapy and 
all studied patients have no evidence of anemia, leucopenia and 
thrombocytopenia. These base line parameters are in agree with 
[39] who showed how to evaluate the efficacy of combination of 
standard interferon α2b and ribavirin in chronic hepatitis C. All 
included 126 patients showed normal base line hematological 
parameters. Side effects of treatment however are essentially 
universal. These led to modification of the dosage of interferon 
and/or ribavirin in 35-42 % of patients treated with peg-interferon, 
in large randomized clinical trials and discontinuation of therapy in 
14-19 % of these patients [42]. Patients were defined as having 
hematological abnormalities if they had presence of anemia, 
neutropenia, thrombocytopenia, or a combination of the above 
during treatment with interferon and ribavirin [43].  
The most frequent hematological abnormalities including anemia, 
thrombocytopenia, and leucopenia are commonly seen in patients 
with chronic hepatitis C treated with combined antiviral treatment 
[44]. In the present study, a highly significant decrease in 
hemoglobin level was observed in group one after treatment as 
compared to before treatment. Anemia with hemoglobin levels 
below 10 gm was detected in 25 % of cases at week 12. A 
modification of treatment occurred and 10 % of cases show marked 
anemia with hemoglobin level ≤8.0g/dl which led to the 
discontinuance of treatment. In group two, we found a highly 
significance decrease in hemoglobin concentration after treatment. 
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There were 4 cases (20 %) showing hemoglobin less than 10 mg/dl 
and 1 case (5 %) showed marked anemia forcing the discontinuance 
of treatment. Furthermore, this study demonstrates that 30 % of the 
studied patients (12/40) had decrease in Hb below 10 gm, 7 cases of 
group one and 5 cases of group two. These results of the current 
study are in agreement with those of [42] who found that>20 % of 
patients treated with a peg-interferon and ribavirin at 1,000-1,200 
mg/day had marked anemia. Because ribavirin-induced hemolysis 
destroys a portion of the available pool of erythrocytes, a high pre-
treatment level of hemoglobin was the logical explanation for its 
large decrease. Erythrocytes selectively accumulate RBV 
metabolites, sustained oxidative membrane damage and become 
subject to increased extra vascular hemolysis in the 
reticuloendothelial system. In addition, the IFNs can directly 
suppress bone marrow erythropoiesis. Ribavirin itself has also been 
reported to have myelosuppressive properties [45]. Furthermore, 
[39] found that the mean hemoglobin concentration fell from 
13.2±1.2 g per deciliter to 11.2±1.6 g per deciliter during the first 
month of treatment. The values fell below 10 g per deciliter in 10 
patients and below 9 g per deciliter in 3 patients.  
As regarding the total leucocytes count, the present data 
demonstrated that treatment with peg-interferon and ribavirin 
showed a highly significant decrease in white blood cells count after 
treatment as compared to before treatment in group one and group 
two. The present results revealed the incidence of leucopenia with 
decreased WBCs (3000 cell/ml3) in 15 % of cases after 12 w of 
therapy. These data are consistent with [42] who found that 
approximately 20 % of treated patients had neutropenia. Also, [45] 
noted that patients receiving PEG-IFN alpha-2b and RBV have dose 
modifications for neutropenia in 18 % of patients receiving 1.5 
mcg/kg of PEG-IFN alpha-2b. Also, [39] found that white blood cells 
decreased by 35 % and neutrophil count were reduced by 25 % after 
4 w of treatment. 
The present result indicated that there were significant decreases in 
platelets count during interferon and ribavirin therapy. Patients that 
had platelets count below 120.000 cell/m3 during the course of 
treatment was 25 % of group one and 15 % of group two. Also, 
obtained results demonstrated that there was non-significant 
difference in the mean change of platelets in comparing diabetic and 
non-diabetic patients after treatment.  
Moreover, [46] found that only around 4-6 % of patients receiving 
PEG-IFN alpha-2a and RBV required dose reductions for 
thrombocytopenia. This was broadly comparable with patients 
treated with the PEG-IFN alpha-2b/RBV combination (3 %) and 
standard IFN/RBV (1 %). Additionally, [45] reported that interferon 
therapy frequently results in a 10-50 % fall in the platelet count. 
Moreover, [39] recorded that the platelet counts as a biological 
response also fell by 7 % only in five patients. Possible mechanisms 
include a relative thrombopoietin deficiency, impaired 
thrombopoietin signal transduction in megakaryocytes and in some 
cases increased immune-mediated sequestration of platelets. Also, 
the high incidence of thrombocytopenia observed in the two 
previous studies may be attributed to association with 
hypersplenism; low baseline platelets count [46].  
Furthermore, [43] studied the hematological abnormalities during 
treatment with interferon and ribavirin in 136 patients with chronic 
hepatitis C showed 52 (38.2 %) of the patients developed significant 
hematological abnormalities with 28 (20.6 %), 30 (22.1 %), and11 
(8.1 %) developed neutropenia, anemia, thrombocytopenia.  
The present study demonstrated that there were significant 
difference in the mean change of hemoglobin concentration in group 
one as compared to group two, and a highly significant difference in 
WBCs in group one as compared to group two after combination of 
interferon and ribavirin therapy. From above mentioned results, 
data demonstrated that the hematological abnormalities during 
therapy were more frequent in diabetic compared to non-diabetic 
HCV patients.  
In the present study measurement of serum HCV-RNA after 12 w of 
starting antiviral therapy used as a predictor of response, which 
proved that clearance of serum HCV-RNA was more likely in patients 
with lower pre-treatment HCV RNA concentration and they had a 
high likelihood of achieving a sustained response. It was clear from 
the presented data that in group one diabetic CHC patients, 7 non 
responder patients showed 2 patients with moderate and 5 patients 
with high viremia. On the other hand, in group two non-diabetic CHC 
patients, the only non-responder case was with high viremia. These 
results are in agreement with [47] who reported that high baseline 
viral load means that the virus is reproducing rapidly and viral 
cure/SVR may be less likely to occur. Patients with a significant 
decrease in HCV-RNA may demonstrate decreased serum liver 
enzyme, e. g., alanine aminotransferase (ALT) levels and reduced 
liver tissue damage [48]. Additionally,  (49) reported that a higher 
HCV RNA level predicts a lower response rate. The impact of HCV 
RNA level on the response to combination therapy was different 
between patients with different HCV genotype infections. High viral 
load influenced the response rate in patients with HCV-1 (41 % 
versus 56 %) but not those in patients with HCV-2 or HCV-3 (74 % 
versus 81 %). Above mentioned results showed that clearance of 
serum HCV RNA was more likely in patients with lower pre-
treatment HCV-RNA concentration. The present study revealed that 
there was a significant decrease in diabetic response when 
compared to non-diabetic patients to antiviral combination therapy 
with a sustained virological response (SVR) in 65.0 % of patients 
with CHC and type 2 diabetes mellitus and on the other hand 95 % of 
CHC patients without diabetes mellitus showed SVR. Furthermore, 
[38] found that sustained virological response (SVR) occurred in 23 
of 70 (32.8 %) of patients with genotype 1 and insulin resistance, 
while in 26 of 43 (60.5 %) of genotype 1 patient without insulin 
resistance. These findings were independently extended to non-
responders with genotypes 2 and 3 [50]. The present results are 
consistent with the results of [51] who study the influence of DM on 
the outcome of INF-alpha2b plus ribavirin therapy. In a cohort of 
110 patients with CHC, the outcome therapy was evaluated by 
comparing the patients with and without DM. There were 46 
sustained–responders while 64 patients did not become sustained 
responders which indicated that DM reduces the response to INF-
alpha plus ribavirin therapy in CHC patients of genotype1.  
Combination therapy has brought their rate of long-term viral 
clearance and significantly advanced the treatment of chronic 
hepatitis C and represents the current standard of care [52]. An 
SVR is the optimal outcome of HCV therapy. Liver inflammation 
improves and the rate of fibrosis progression is slowed [53]. A 2-
10 folds increase in type 2 DM has been reported worldwide in 
HCV-positive patients when compared with patients with other 
forms of liver diseases [54]. From the clinical standpoint, insulin 
resistance accelerates fibrogenesis and impairs response to IFN-α-
based antiviral therapy [38]. Moreover [55], showed that in a 
study of 1059 patients with chronic HCV the sustained virological 
response (SVR) rate was lower in patients with impaired fasting 
glucose (IFG) and/or T2DM than in patients with normal glucose 
concentrations.  
Additionally, [56] reported that IR and type 2diabetes (T2DM) not 
only accelerate the histological and clinical progression of chronic 
hepatitis C, but also reduce the early and sustained virological 
response to antiviral therapy. Furthermore, [57] reported that 
glycemic control in chronic hepatitis C, could improve the prognosis 
and the response to antiviral treatment. From the above mentioned 
studies, type 2 DM was associated with impaired virological 
response to Peg-INF/RBV in CHC patients.  
In conclusion, the present study has shown that type 2 diabetes 
mellitus in CHC predicts a poor response to antiviral therapy and 
predict faster progression to fibrosis and cirrhosis that may be 
culminates in liver failure and hepatocellular carcinoma. The 
delayed biochemical response during therapy was more frequent in 
diabetic compared to non-diabetic CHC patients. 
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